Core Viewpoint - The company, Yuyantang, has submitted its prospectus to the Hong Kong Stock Exchange, with Zhuhai International and Guoyuan International acting as joint sponsors, focusing on a "full lifecycle diagnosis and treatment model" based on Traditional Chinese Medicine (TCM) principles [1] Group 1: Business Model - The company operates on a "preventive treatment" philosophy, covering four stages: "pre-disease, desire for disease, existing disease, and post-recovery," providing integrated personalized health solutions that include prevention, adjustment, treatment, and maintenance [1] - Yuyantang employs a strict model of "offline initial diagnosis and online follow-up," ensuring all patients complete diagnostic assessments at licensed offline institutions, while the online platform manages follow-ups, chronic disease care, and health management to ensure service continuity [1] Group 2: Market Position - According to a Frost & Sullivan report, Yuyantang ranks as the second-largest private chain TCM healthcare service provider in Northern China by total revenue from TCM outpatient services and clinics as of 2024, and it ranks first in revenue from medicinal pastes [1] - The company boasts the highest customer repurchase rate among private chain TCM healthcare service providers, achieving a repurchase rate of 81.1% for the nine months ending September 30, 2025 [1] Group 3: Infrastructure and Expertise - Yuyantang has established a network of 48 self-built and operated licensed medical institutions in Northern China, all managed through a unified cloud-based healthcare information system (HIS) for digital management [1] - The company offers personalized TCM prescriptions, including decoctions, pills, powders, and pastes, and possesses proprietary non-heritage pastes and several in-house developed formulations as protected therapeutic assets [1] - Yuyantang employs 292 full-time medical professionals, with a research committee comprising 98 experts, integrating knowledge from both internal medical teams and external research collaborators [1]

Core Viewpoint - Harbin Yuyuantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance its market position in the traditional Chinese medicine sector [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyuantang's full lifecycle diagnosis and treatment model covers disease prevention, adjustment, treatment, and health maintenance, providing personalized and continuous health management services [2][7]. - The company has established a network of 48 self-operated licensed medical institutions in Northern China, utilizing a unified cloud-based medical information system for digital management [2][6]. Group 2: Market Position and Customer Loyalty - According to a report by Frost & Sullivan, Yuyuantang ranks second among private chain TCM medical service providers in Northern China by total revenue and first in revenue from medicinal pastes [1]. - The company's customer repurchase rate reached 81.1% as of September 30, 2025, indicating strong market recognition of its service value and efficacy [3]. Group 3: Product Development and Supply Chain - Yuyuantang adheres to the "one person, one prescription" principle, offering various personalized traditional Chinese medicine formulations, including decoctions, pills, powders, and pastes [4]. - The company has developed proprietary non-heritage pastes that enhance patient compliance and serve as key components in chronic disease management [4]. - Yuyuantang is focused on building a dedicated facility for producing traditional Chinese medicine pieces, ensuring supply chain security and quality control through vertical integration [6]. Group 4: Strategic Outlook - The company plans to expand its geographic footprint in provinces such as Shandong, Hebei, Henan, and Tianjin, while enhancing resource allocation and market influence [6]. - With the ongoing implementation of the "Healthy China 2030" initiative and various TCM revitalization policies, the market for TCM medical services is poised for systematic growth, aligning with the increasing demand for long-term health management [7].

Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance patient care and capitalize on the growing demand for traditional Chinese medicine services in China [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyantang's "full lifecycle diagnosis and treatment model" covers the stages of "preventive care, disease management, treatment, and recovery," providing personalized health management solutions through modern TCM assessment tools and big data analysis [2][3]. - The company has established a network of 48 self-operated licensed medical institutions in northern China, utilizing a unified cloud-based medical information system for digital management [3]. Group 2: Product Offerings - Yuyantang adheres to the "one person, one prescription" principle, offering various personalized TCM formulations, including decoctions, pills, powders, and ointments, which enhance patient compliance and serve as key components in chronic disease management [4]. - The company has proprietary non-heritage ointments and several self-developed hospital formulations that are continuously refined based on clinical experience, forming a standardized and clinically validated foundation for its services [4]. Group 3: Talent and Team Structure - The company employs 292 full-time medical professionals, ensuring stable and continuous service quality, while its research committee consists of 98 experts, driving innovation and maintaining high standards in patient care [5]. Group 4: Supply Chain and Production Strategy - Yuyantang's core strategy includes building a dedicated facility for producing TCM raw materials, which enhances supply chain security and quality control from raw materials to final products [6]. - The company aims to expand its regional presence in provinces such as Shandong, Hebei, Henan, and Tianjin, while digitally transforming its production facilities to ensure quality assurance [6]. Group 5: Market Opportunities - The traditional Chinese medicine service market is experiencing systemic growth opportunities due to the "Healthy China 2030" initiative and various TCM revitalization policies, aligning with the increasing demand for long-term health management [7]. - Yuyantang's innovative service model and integrated operational ecosystem position it well for accelerated growth through its upcoming public listing, reflecting a shift in the private TCM sector towards standardized and sustainable high-quality development [7].